Summit Therapeutics announces global Phase II study of ivonescimab regimens in advanced clear cell renal cell carcinoma
SMMT•Summit Therapeutics announced the opening of a global Phase II study evaluating ivonescimab alone and with cadonilimab or ipilimumab in advanced clear cell renal cell carcinoma.
1. Study regimens
The Phase II study will evaluate ivonescimab alone and in combination with cadonilimab or ipilimumab in advanced clear cell renal cell carcinoma.
